Psyence Biomedical Ltd. has 5 Schedule 13D or 13G filings on record since 2025-12-10. 1 holder's latest filing reports 5% or more of common shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Psyence Labs Ltd. | 30.05% | 1,146,159 | SCHEDULE 13D, 2026-06-03 | 2026-02-25 |
| KAOS Capital Ltd. | 4.91% | 313,876 | SCHEDULE 13D/A, 2026-01-13 | 2026-01-08 |
| Weiner Jeffrey David | 2.61% | 59,750 | SCHEDULE 13G/A, 2026-06-10 | 2026-02-25 |
Purpose of Transaction (Item 4)
KAOS Capital Ltd.
The Reporting Persons believe the securities of the Issuer represent an attractive investment opportunity but have significant concerns about the current management of the Company's assets. The Reporting Persons intend to communicate with the Issuer's management and Board about a broad range of operational, management, corporate and strategic matters including corporate governance and strategic alternatives, and may communicate with other shareholders or third-parties about such matters. In particular, the Reporting Persons believe that the Issuer would benefit from the addition of alternative directors and a change in strategy. The Reporting Persons may also take other actions to influence the Issuer's management or policies. The Reporting Persons intend to continue to review their investment in the Issuer on a continuing basis, and depending upon various factors, including without limitation, the Issuer's financial position and strategic direction, the outcome of any discussions referenced above, overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of securities of the Issuer at prices that would make the purchase or sale of such securities desirable, the Reporting Persons may endeavor (i) to increase or decrease their position in the Issuer through, among other things, the purchase or sale of securities of the Issuer, including through transactions involving the shares Common Stock and/or other equity, debt, …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-01-13; the filing has the rest
Psyence Labs Ltd.
The Reporting Person acquired the Subject Shares pursuant to the exercise of an irrevocable put option granted to the Reporting Person under the Put Option Agreement. As previously disclosed by the Issuer in its Report on Form 6-K furnished to the Securities and Exchange Commission on February 13, 2026, the Reporting Person exercised the put option to require the Issuer to subscribe for US$5,000,000 of ordinary shares of the Reporting Person, with such subscription consideration to be satisfied through the issuance of Common Shares of the Issuer pursuant to the Share Exchange. The Reporting Person acquired the Subject Shares for investment purposes. The Reporting Person intends to review its investment in the Issuer on a continuing basis and may, from time to time and at any time, depending on various factors, including, without limitation, the Issuer's financial position and strategic direction, actions taken by the Issuer's board of directors (the "Board"), price levels of the Common Shares, conditions in the securities market, and general economic and industry conditions, take such actions with respect to its investment in the Issuer as it deems appropriate, including, without limitation: (i) acquiring additional Common Shares and/or other equity, debt, notes, instruments or other securities of the Issuer (collectively, "Securities") in the open market, in privately negotiated transactions, or otherwise; (ii) disposing of any or all of the Securities in the open market, …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-03; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-12-10 | KAOS Capital Ltd. | 16.77% | SCHEDULE 13D |
| 2026-01-13 | KAOS Capital Ltd. | 4.91% | SCHEDULE 13D/A |
| 2026-02-19 | Weiner Jeffrey David | 5.07% | SCHEDULE 13G |
| 2026-06-03 | Psyence Labs Ltd. | 30.05% | SCHEDULE 13D |
| 2026-06-10 | Weiner Jeffrey David | 2.61% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Psyence Biomedical Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.